Almac Clinical Services presents a podcast episode of The Top Line from Fierce Biotech, where Olive McCormick, Director of Quality, joins Chris Hayden from Fierce to explore the overlooked risk of last-minute surprises in clinical trials. Drawing on her experience, McCormick explains how late-stage issues can threaten patient safety, delay progress and damage credibility.
The discussion highlights the need for strong communication, clear accountability and early alignment on operational and regulatory expectations — particularly in light of the UK Clinical Trial Regulation coming into force on April 28, 2026. Ultimately, success depends on a proactive, coordinated approach to trial execution that minimizes risk and builds trust with patients and regulators.
For further insights listen to the Podcast today.